Lung Cancer Clinical Trials in Arizona

Showing 521-533 of 533 trials

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

NCT00909558

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.

Breast CancerGliomaHepatocellular Cancer+4 more

Envita Medical Center, Inc.24 participantsStarted May 2009

Scottsdale, Arizona, United States

COMPLETEDPhase 242 miles

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969

The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or progressive.

Small Cell Lung Cancer

Celgene Corporation76 participantsStarted Apr 2006

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Berkeley, California, United States +44 more locations

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Lung Cancer Trials in Other Cities

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Arizona